Discover
AVTX
Avalo Therapeutics, Inc.
17.29
2 x 13.40
2 x 22.24
bid
ask
-
1.19
6.44%
2 @ 05:44 AM
17.61 +0.32 (1.85%)
| Ytd | -4.79% | |
| 1y | 257.23% |
17.23
day range
18.99
4.61
52 week range
24.27
| Open | 18.43 | Prev Close | 18.48 | Low | 17.23 | High | 18.99 | Mkt Cap | 908.86M |
| Vol | 1.85M | Avg Vol | 1.94M | EPS | -5.57 | P/E | N/A | Forward P/E | -6.89 |
| Beta | 0.82 | Short Ratio | 5.22 | Inst. Own | 76.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 16.09 | 200-d Avg | 15.84 | 1yr Est | 45.25 |
| Income Statement | |||
| Operating Expenses | 20.90M | ||
| Research and Development Expense | 14.05M | ||
| Selling, General and Administrative Expense | 6.85M | ||
| Operating Income | -20.90M | ||
| Income Tax Expense | 12.00K | ||
| Net Income | -19.63M | ||
| Net Income Common Stock | -19.63M | ||
| Net Income Common Stock (USD) | -19.63M | ||
| Consolidated Income | -19.63M | ||
| Earnings per Basic Share | -0.98 | ||
| Earnings per Basic Share (USD) | -0.98 | ||
| Earnings per Diluted Share | -0.98 | ||
| Earning Before Interest & Taxes (EBIT) | -19.62M | ||
| Earning Before Interest & Taxes (USD) | -19.62M | ||
| Weighted Average Shares | 20.11M | ||
| Weighted Average Shares Diluted | 20.11M | ||
| Balance Sheet | |||
| Cash and Equivalents | 25.14M | ||
| Cash and Equivalents (USD) | 25.14M | ||
| Investments | 57.19M | ||
| Investments Current | 57.01M | ||
| Investments Non-Current | 183.00K | ||
| Current Assets | 88.83M | ||
| Property, Plant & Equipment Net | 375.00K | ||
| Total Assets | 99.89M | ||
| Current Liabilities | 11.60M | ||
| Total Liabilities | 31.57M | ||
| Accumulated Retained Earnings (Deficit) | -468.15M | ||
| Accumulated Other Comprehensive Income | -6.00K | ||
| Shareholders Equity | 68.32M | ||
| Shareholders Equity (USD) | 68.32M | ||
| Assets Non-Current | 11.06M | ||
| Goodwill and Intangible Assets | 10.50M | ||
| Liabilities Non-Current | 19.97M | ||
| Trade and Non-Trade Payables | 356.00K | ||
| Tax Liabilities | 446.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 17.00K | ||
| Net Cash Flow from Financing | 1.40M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 9.21M | ||
| Issuance (Purchase) of Equity Shares | 2.18M | ||
| Net Cash Flow from Investing | 25.51M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 25.51M | ||
| Net Cash Flow from Operations | -17.69M | ||
| Share Based Compensation | 3.58M | ||